Which has preferable earnings and valuation, BBNX or AXGN?

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 5.53 -$73.20M -$1.51 N/A AxoGen $225.21M 9.59 -$15.70M -$0.64 N/A

Is BBNX or AXGN more profitable?

AxoGen has a net margin of -13.21% compared to Beta Bionics' net margin of -60.27%. AxoGen's return on equity of -9.63% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% AxoGen -13.21% -9.63% -6.26%

Does the media favor BBNX or AXGN?

In the previous week, Beta Bionics had 12 more articles in the media than AxoGen. MarketBeat recorded 14 mentions for Beta Bionics and 2 mentions for AxoGen. AxoGen's average media sentiment score of 1.77 beat Beta Bionics' score of 0.43 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BBNX or ESTA?

In the previous week, Beta Bionics had 12 more articles in the media than Establishment Labs. MarketBeat recorded 14 mentions for Beta Bionics and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.49 beat Beta Bionics' score of 0.43 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NVCR or BBNX?

Beta Bionics has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.85 -$136.23M -$1.53 N/A Beta Bionics $100.25M 5.53 -$73.20M -$1.51 N/A

Is NVCR or BBNX more profitable?

NovoCure has a net margin of -25.66% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Beta Bionics -60.27% -23.00% -20.55%

Does the media prefer NVCR or BBNX?

In the previous week, Beta Bionics had 6 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for Beta Bionics and 8 mentions for NovoCure. NovoCure's average media sentiment score of 0.93 beat Beta Bionics' score of 0.43 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRCT or BBNX?

In the previous week, Beta Bionics had 10 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 14 mentions for Beta Bionics and 4 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 0.61 beat Beta Bionics' score of 0.43 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Beta Bionics (BBNX) Competitors

$12.45 -0.34 (-2.69%)

Closing price 06/3/2026 03:58 PM Eastern

Extended Trading

$12.58 +0.14 (+1.12%)

As of 06/3/2026 06:22 PM Eastern

Compare

BBNX vs. AXGN, ESTA, NVCR, PLSE, and PRCT

Should you buy Beta Bionics stock or one of its competitors? MarketBeat compares Beta Bionics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beta Bionics include AxoGen (AXGN), Establishment Labs (ESTA), NovoCure (NVCR), Pulse Biosciences (PLSE), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry.

How does Beta Bionics compare to AxoGen?

Beta Bionics (NASDAQ:BBNX) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	5.53	-$73.20M	-$1.51	N/A
AxoGen	$225.21M	9.59	-$15.70M	-$0.64	N/A

AxoGen has a net margin of -13.21% compared to Beta Bionics' net margin of -60.27%. AxoGen's return on equity of -9.63% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
AxoGen	-13.21%	-9.63%	-6.26%

80.3% of AxoGen shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Beta Bionics presently has a consensus target price of $19.70, suggesting a potential upside of 58.28%. AxoGen has a consensus target price of $46.50, suggesting a potential upside of 14.45%. Given Beta Bionics' higher possible upside, equities research analysts plainly believe Beta Bionics is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Beta Bionics has a beta of 3.4, indicating that its stock price is 240% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

In the previous week, Beta Bionics had 12 more articles in the media than AxoGen. MarketBeat recorded 14 mentions for Beta Bionics and 2 mentions for AxoGen. AxoGen's average media sentiment score of 1.77 beat Beta Bionics' score of 0.43 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

AxoGen beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Establishment Labs?

Beta Bionics (NASDAQ:BBNX) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

72.9% of Establishment Labs shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 10.0% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beta Bionics has a beta of 3.4, suggesting that its share price is 240% more volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Establishment Labs has a net margin of -19.05% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Establishment Labs	-19.05%	-218.77%	-12.31%

Establishment Labs has higher revenue and earnings than Beta Bionics. Establishment Labs is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	5.53	-$73.20M	-$1.51	N/A
Establishment Labs	$211.08M	10.10	-$51.06M	-$1.49	N/A

Beta Bionics presently has a consensus target price of $19.70, indicating a potential upside of 58.28%. Establishment Labs has a consensus target price of $87.14, indicating a potential upside of 20.35%. Given Beta Bionics' stronger consensus rating and higher probable upside, research analysts plainly believe Beta Bionics is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Beta Bionics had 12 more articles in the media than Establishment Labs. MarketBeat recorded 14 mentions for Beta Bionics and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.49 beat Beta Bionics' score of 0.43 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Establishment Labs beats Beta Bionics on 9 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Beta Bionics has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.85	-$136.23M	-$1.53	N/A
Beta Bionics	$100.25M	5.53	-$73.20M	-$1.51	N/A

84.6% of NovoCure shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Beta Bionics had 6 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for Beta Bionics and 8 mentions for NovoCure. NovoCure's average media sentiment score of 0.93 beat Beta Bionics' score of 0.43 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has a net margin of -25.66% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Beta Bionics	-60.27%	-23.00%	-20.55%

NovoCure currently has a consensus target price of $27.29, suggesting a potential upside of 68.95%. Beta Bionics has a consensus target price of $19.70, suggesting a potential upside of 58.28%. Given NovoCure's higher probable upside, equities research analysts plainly believe NovoCure is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

NovoCure has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, indicating that its share price is 240% more volatile than the broader market.

Summary

Beta Bionics beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Pulse Biosciences?

Beta Bionics (NASDAQ:BBNX) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

77.0% of Pulse Biosciences shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Beta Bionics had 13 more articles in the media than Pulse Biosciences. MarketBeat recorded 14 mentions for Beta Bionics and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.93 beat Beta Bionics' score of 0.43 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Beta Bionics	Neutral
Pulse Biosciences	Positive

Beta Bionics currently has a consensus price target of $19.70, suggesting a potential upside of 58.28%. Pulse Biosciences has a consensus price target of $30.00, suggesting a potential upside of 20.05%. Given Beta Bionics' stronger consensus rating and higher possible upside, equities analysts clearly believe Beta Bionics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pulse Biosciences has lower revenue, but higher earnings than Beta Bionics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	5.53	-$73.20M	-$1.51	N/A
Pulse Biosciences	$350K	4,941.59	-$72.78M	-$1.10	N/A

Beta Bionics has a beta of 3.4, meaning that its share price is 240% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Pulse Biosciences has a net margin of 0.00% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Pulse Biosciences	N/A	-86.67%	-73.61%

Summary

Beta Bionics beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

PROCEPT BioRobotics currently has a consensus target price of $41.45, suggesting a potential upside of 57.44%. Beta Bionics has a consensus target price of $19.70, suggesting a potential upside of 58.28%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts clearly believe Beta Bionics is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Beta Bionics has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.87	-$95.57M	-$1.82	N/A
Beta Bionics	$100.25M	5.53	-$73.20M	-$1.51	N/A

In the previous week, Beta Bionics had 10 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 14 mentions for Beta Bionics and 4 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 0.61 beat Beta Bionics' score of 0.43 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PROCEPT BioRobotics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, suggesting that its share price is 240% more volatile than the broader market.

PROCEPT BioRobotics has a net margin of -31.82% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Beta Bionics	-60.27%	-23.00%	-20.55%

Summary

Beta Bionics beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$569.94M	$7.25B	$6.47B	$12.54B
Dividend Yield	N/A	1.23%	2.69%	5.22%
P/E Ratio	-8.24	45.06	22.17	24.18
Price / Sales	5.53	74.02	520.79	112.26
Price / Cash	N/A	24.22	41.34	57.13
Price / Book	1.91	7.15	9.84	6.72
Net Income	-$73.20M	$159.22M	$3.57B	$337.19M
7 Day Performance	2.86%	-2.00%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-36.01%	0.95%	26.49%	33.10%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	3.4344 of 5 stars	$12.45 -2.7%	$19.70 +58.3%	-30.7%	$569.94M	$100.25M	N/A	294	Trending News
AXGN AxoGen	2.9602 of 5 stars	$39.48 -2.3%	$46.50 +17.8%	+257.7%	$2.10B	$225.21M	N/A	450	Positive News
ESTA Establishment Labs	2.8926 of 5 stars	$70.69 -3.1%	$87.14 +23.3%	+97.3%	$2.08B	$211.08M	N/A	1,004	Positive News
NVCR NovoCure	2.8379 of 5 stars	$17.04 -1.2%	$27.29 +60.1%	-5.2%	$1.97B	$655.35M	N/A	1,605	Analyst Upgrade
PLSE Pulse Biosciences	2.5306 of 5 stars	$25.00 +1.1%	$30.00 +20.0%	+41.7%	$1.73B	$350K	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. AXGN, ESTA, NVCR, PLSE, and PRCT

How does Beta Bionics compare to AxoGen?

Summary

How does Beta Bionics compare to Establishment Labs?

Summary

How does Beta Bionics compare to NovoCure?

Summary

How does Beta Bionics compare to Pulse Biosciences?

Summary

How does Beta Bionics compare to PROCEPT BioRobotics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. AXGN, ESTA, NVCR, PLSE, and PRCT

How does Beta Bionics compare to AxoGen?

Which has preferable earnings and valuation, BBNX or AXGN?

Is BBNX or AXGN more profitable?

Do institutionals and insiders hold more shares of BBNX or AXGN?

Do analysts rate BBNX or AXGN?

Which has more volatility & risk, BBNX or AXGN?

Does the media favor BBNX or AXGN?

Summary

How does Beta Bionics compare to Establishment Labs?

Do institutionals and insiders believe in BBNX or ESTA?

Which has more risk and volatility, BBNX or ESTA?

Is BBNX or ESTA more profitable?

Which has better valuation & earnings, BBNX or ESTA?

Do analysts prefer BBNX or ESTA?

Does the media favor BBNX or ESTA?

Summary

How does Beta Bionics compare to NovoCure?

Which has stronger valuation & earnings, NVCR or BBNX?

Do institutionals & insiders believe in NVCR or BBNX?

Does the media prefer NVCR or BBNX?

Is NVCR or BBNX more profitable?

Do analysts prefer NVCR or BBNX?

Which has more risk & volatility, NVCR or BBNX?

Summary

How does Beta Bionics compare to Pulse Biosciences?

Do institutionals and insiders hold more shares of BBNX or PLSE?

Does the media refer more to BBNX or PLSE?

Do analysts prefer BBNX or PLSE?

Which has stronger earnings and valuation, BBNX or PLSE?

Which has more risk and volatility, BBNX or PLSE?

Is BBNX or PLSE more profitable?

Summary

How does Beta Bionics compare to PROCEPT BioRobotics?

Do analysts recommend PRCT or BBNX?

Which has higher valuation & earnings, PRCT or BBNX?

Does the media prefer PRCT or BBNX?

Do insiders and institutionals hold more shares of PRCT or BBNX?

Which has more volatility & risk, PRCT or BBNX?

Is PRCT or BBNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools